Treprostinil (Remodulin)

Remodulin (treprostinil) is covered for WHO Group I pulmonary arterial hypertension (including transition from epoprostenol) and compendial off‑label use for chronic thromboembolic pulmonary hypertension (CTEPH), while uses outside WHO Group I PAH are not supported. Key requirements include right‑heart catheterization confirmation of WHO Group I PAH, documented NYHA functional class III/IV (or class II with prior oral or inhaled/parenteral prostacyclin trial), specialist prescribing/consultation (pulmonologist or cardiologist), continuous subcutaneous or IV infusion within dose limits (≤100 ng/kg/min for PAH, ≤50 ng/kg/min for CTEPH), documented benefit for reauthorization, 12‑month approvals, and up to a 30‑day short supply if documentation is lacking.

"Idiopathic PAH: has tried one CCB."

Sign up to see full coverage criteria, indications, and limitations.